Results 211 to 220 of about 2,190,408 (347)

Efficacy of Inebilizumab in N‐MOmentum Trial Participants With or Without Prior Immunosuppressants

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT This post hoc analysis examined the impact of prior immunosuppressants on the long‐term efficacy and safety of inebilizumab, a cluster of differentiation 19+ B‐cell–depleting monoclonal antibody, in participants with aquaporin‐4–seropositive neuromyelitis optica spectrum disorder from the N‐MOmentum trial (NTC02200770).
Bruce A. C. Cree   +9 more
wiley   +1 more source

Horizon scanning at EMA: preparing for the medicines of the future. [PDF]

open access: yesFront Med (Lausanne)
Correia PD   +6 more
europepmc   +1 more source

Sarilumab in Polyarticular‐Course Juvenile Idiopathic Arthritis: Dose‐Finding and 1‐Year Analysis of a Phase 2b, Open‐Label, Multicenter Study

open access: yesArthritis Care &Research, EarlyView.
Objective This study assessed sarilumab in treating patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods This phase 2b, open‐label study (NCT02776735) consisted of three sequential parts (each with a core‐treatment and extension phase).
Fabrizio De Benedetti   +19 more
wiley   +1 more source

Validation of a Genetic Risk Score Combined With Clinical Variables for Predicting Pulmonary Fibrosis in Early Rheumatoid Arthritis

open access: yesArthritis Care &Research, EarlyView.
Objective Pulmonary fibrosis (PF) is a severe extra‐articular manifestation of rheumatoid arthritis (RA). This study aimed to externally validate a genetic risk score (GRS) and a combined risk score (CRS) for predicting the risk of RA‐associated PF in an independent cohort of patients with early RA.
Mikael Brink   +3 more
wiley   +1 more source

Safety of carbon dioxide extract from <i>Cannabis sativa</i> L. as a novel food pursuant to Regulation (EU) 2015/2283. [PDF]

open access: yesEFSA J
EFSA Panel on Nutrition   +34 more
europepmc   +1 more source

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients With Systemic Lupus Erythematosus: A Multicenter, Open‐Label Trial

open access: yesArthritis Care &Research, EarlyView.
Objective This study aimed to characterize the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of subcutaneous belimumab in pediatric patients with active systemic lupus erythematosus (SLE) receiving standard therapy. Methods This single‐arm, multicenter, open‐label trial (GSK study 200908; ClinicalTrials.gov identifier ...
Hermine I. Brunner   +14 more
wiley   +1 more source

Moderators of the Effects of Exercise and Manual Therapy for People With Knee and Hip Osteoarthritis: A Secondary Analysis of a Randomized Clinical Trial

open access: yesArthritis Care &Research, EarlyView.
Objective This study aimed to investigate potential moderators influencing the effects of manual therapy and exercise therapy on pain and functional outcomes in individuals with knee and/or hip osteoarthritis, using data from the MOA trial. This is a secondary analysis of data from the MOA trial that compares the clinical effectiveness of manual ...
Daniel Cury Ribeiro   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy